Temple University’s Center for Public Health Law Research published the first 50-state-plus-D.C. map of prior authorization rules for pediatric ADHD medication in Medicaid managed care on September 10, 2026. MedicalXpress picked it up that same week, and CHADD flagged it in its research roundup a few days later.

The timing isn’t great. Fall is when pediatric ADHD diagnoses reliably spike — new school year, new teacher, and suddenly the thing summer let slide gets a name. Stimulant shortages are already turning pharmacy runs into a multi-store scavenger hunt for families with a prescription in hand. And now there’s a dataset showing, state by state and plan by plan, exactly which Medicaid managed care plans make getting that prescription approved harder in the first place.

This isn’t a small slice of the ADHD population, either. Most kids on Medicaid — more than 85% of them — get their coverage through a managed care plan, not old-school fee-for-service Medicaid. Whatever this data shows about managed care is, for practical purposes, the story of Medicaid ADHD medication access nationally.

The Prior Authorization Numbers, Fast

• 158 Medicaid managed care plans cover pediatric ADHD medication, across 31 states plus D.C., as of October 1, 2025
• 129 of 158 — 82% — attach prior authorization, an age limit, or both before a kid’s prescription gets filled
• 28 states have at least one plan doing this
• 14 plans require documented proof behavioral therapy already failed
• 7 plans require the kid to be in behavioral therapy at the same time as taking the medication
• 85%+ of Medicaid-enrolled kids get coverage through managed care, not fee-for-service — this is the default experience, not an edge case

Our take: These plans are running the same utilization-management playbook built for adult stimulant diversion risk on second-graders, largely unchanged. That mismatch — not the paperwork itself — is the real story here.

What Temple Actually Measured

This isn’t a survey or an estimate. It’s policy surveillance — researchers pulled the actual plan documents, provider manuals, and preferred drug lists from Medicaid managed care plans in every state and D.C., then coded what each one requires before it’ll pay for a stimulant or non-stimulant ADHD prescription for a kid under 18.

As of October 1, 2025, 158 Medicaid managed care plans across 31 states cover pediatric ADHD medication in a way the researchers could document. Of those, 129 plans — spread across 28 states — attach a prior authorization requirement, an age restriction, or both before that coverage kicks in for a child under 18.

Two smaller categories go further than a paperwork checkbox:

• 14 plans require documented proof that behavioral therapy was already tried and failed before they’ll approve medication.
• 7 plans require the child to be enrolled in, or actively referred to, behavioral therapy at the same time as taking the medication — not before, alongside.

Adam Herpolsheimer, JD, the law and policy analyst at Temple’s Center for Public Health Law Research who worked on the dataset, put it plainly: these numbers are “a first step in providing us with a better understanding of the barriers to access children face around the country.” First step is the right framing. This is the map. It doesn’t yet explain why any one state landed where it did, or how long an average approval takes. But you can’t fix what you haven’t mapped, and nobody had this map before.

What Barriers Do Medicaid Plans Put on Kids’ ADHD Medication?

Based on the Temple data, Medicaid managed care plans lean on four tools to control pediatric ADHD medication access:

1. Prior authorization — a prescriber has to get plan sign-off before the pharmacy will fill the script, sometimes every refill, sometimes just the first one.
2. Age restrictions — the plan won’t cover the medication below (or requires extra approval below) a specific age cutoff, regardless of clinical need.
3. Documented behavioral therapy failure — proof that non-medication treatment was tried first and didn’t work, required by 14 plans before medication gets approved.
4. Concurrent behavioral therapy — an active referral or ongoing enrollment in therapy, required alongside medication by 7 plans.

Most of the friction — 129 of 158 plans — comes from the first two. The therapy-related requirements are a smaller slice, but they’re the ones that add the most real-world delay, because behavioral therapy access for kids on Medicaid is its own separate mess of waitlists and provider shortages.

Why This Matters More in September Than in March

We’ve covered how ADHD symptom recognition shifts once a kid hits a classroom setting — a lot of what gets waved off at home in July gets flagged by a teacher in September. That’s not a coincidence, it’s a pattern, and it means diagnosis referrals and new prescriptions cluster hard in fall.

Walk through what that means for a Medicaid family in one of the 28 states with prior authorization requirements. A pediatrician diagnoses ADHD in September. They write a script. The pharmacy holds it pending prior authorization. The plan wants documentation — sometimes a behavioral assessment, sometimes proof of an existing therapy referral — before it approves. That review can take days. Sometimes longer, if paperwork bounces back for more information. Meanwhile the kid is mid-semester, un-medicated, and behind on whatever the diagnosis was supposed to help with.

Now add the medication shortage on top of it. Stimulant shortages have been grinding on for years, and the American Society of Health-System Pharmacists still lists several amphetamine formulations as actively short heading into this fall. A family that clears prior authorization can still hit a pharmacy with nothing on the shelf. Two separate systems, each capable of stalling a kid’s medication on its own, both active at the same time.

The Half That Doesn’t Get Medicated

More than 7 million U.S. children ages 3 to 17 — 11.7% of kids in that age range — have a current ADHD diagnosis, according to the federal government’s National Survey of Children’s Health. Nationally, roughly half of diagnosed kids end up on medication for it.

That’s an all-payer number, not a Medicaid-specific one, and the Temple data doesn’t measure how much of that gap is prior-authorization friction versus cost, versus provider shortages, versus a family deciding medication isn’t the right fit. Be honest about that limit. But it doesn’t take much imagination to guess that a system where 129 of 158 relevant Medicaid plans put a hurdle in front of the prescription is going to push some kids toward the unmedicated half of that statistic who’d otherwise be on the medicated side — especially in the 28 states where a parent has to clear a prior-authorization queue before the prescription reaches a pharmacy shelf at all.

That burden isn’t evenly distributed, either — we’ve covered how language and immigration status compound ADHD diagnosis delays, and the same compounding effect almost certainly applies once a diagnosed kid hits a prior-authorization form.

Where You Are Determines What You Do Next

None of this is medical advice, and none of it substitutes for talking to your child’s prescriber. But the right move depends on where you are in the process — so here’s what changes at each stage.

Before a Diagnosis Is Even On the Table

Call your Medicaid managed care plan and ask now, not later. Member services can tell you, in plain language, whether this plan requires prior authorization for ADHD medication and whether it requires documented behavioral therapy first. Get the answer in writing if you can. You want this information before you need it, not while a pharmacist is holding a script.

If a therapy requirement exists, get on that waitlist before medication is even the topic. Behavioral therapy access is usually the slower bottleneck of the two. A referral started now is already moving by the time a plan asks for proof of it.

At the Moment of Diagnosis

Start the paperwork clock the day the diagnosis happens, not the day symptoms got noticed. If signs showed up in August, don’t wait for the September teacher conference to see a prescriber — the prior-authorization review doesn’t begin until someone submits the form.

Build the documentation file immediately. Diagnostic reports, prior treatment attempts, teacher observations — plans that require “proof” want paper, not a parent’s word. The same pill-tracking discipline that helps once medication starts is worth applying to the paperwork trail before approval even comes through.

After a Denial (or a Pharmacy With Nothing In Stock)

Appeal. Formally, every time. Prior authorization denials aren’t final. Medicaid managed care plans have appeal processes, and pediatricians who handle this regularly often know which forms move fastest — ask the prescribing office directly whether they have a template, because many do.

If the script clears approval but the shelf is empty, ask your prescriber about non-stimulant bridges. This isn’t a DIY swap. But the deprescribing and medication-transition guidance we’ve covered applies just as much to a forced pause as a planned one — the executive function support systems matter more, not less, while access is unstable.

Our Take

A law school research center had to build a 50-state map just to answer a question that should have a simple public answer: does my kid’s Medicaid plan make this hard? That itself says something about how opaque plan-level policy is to the families living inside it.

Prior authorization exists, on paper, because stimulants carry real diversion and misuse risk — the review process was built to catch that problem, largely with adult prescribing patterns in mind. What the Temple map shows is that same review process, mostly unmodified, applied to a seven-year-old who needs a working memory boost to get through third grade. Same forms, same “prove something else was tried first” logic, same review clock, whether the patient is a 34-year-old with a decade of prescribing history or a kid three weeks past their first diagnosis.

129 of 158 plans running an adult-built process on pediatric patients isn’t a few outlier states overcorrecting. It’s the default configuration of Medicaid managed care nationally. The 14 plans demanding proof of failed therapy and the 7 requiring concurrent therapy are a smaller slice, but they’re the clearest example of the mismatch — tying a kid’s medication to a system designed to slow down adult misuse, not to a pediatrician’s clinical judgment.

This data didn’t create that mismatch. It just made it visible enough, state by state, to name.

---

Source: Temple University Center for Public Health Law Research, “New data examine pediatric ADHD medication prior authorization policies in Medicaid managed care plans,” September 10, 2026. Full dataset available at LawAtlas.org. Additional coverage via MedicalXpress and CHADD. ADHD prevalence figures from the CDC’s National Survey of Children’s Health data. This post is not medical or legal advice — talk to your child’s prescriber and your state Medicaid plan about your specific situation.